EOLS - Evolus, Inc.
| Previous Close | 24.15 |
| Open | 24.05 |
| Bid | 24.98 x 1300 |
| Ask | 25.00 x 900 |
| Day's Range | 23.59 - 25.20 |
| 52 Week Range | 6.75 - 39.50 |
| Volume | 366,709 |
| Avg. Volume | 1,248,529 |
| Market Cap | 681.599M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.92 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.50 |
- GlobeNewswire•12 days ago
Evolus Announces Publication of Largest Aesthetic Head-to-Head Pivotal Trial Comparing Jeuveau™ and BOTOX® in Aesthetic Surgery Journal
Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the publication of the European and Canadian Phase III head-to-head pivotal trial results in the April issue of Aesthetic Surgery Journal. “We are pleased that these data were accepted and published in the Aesthetic Surgery Journal, which is added validation of the rigor of the study,” said Rui Avelar, MD, Chief Medical Officer and Head of Research & Development. “The results of this study are compelling and reinforce the clinical performance of Jeuveau™, which is the first 900 kDa product to enter the U.S. market in nearly 30 years,” said David Moatazedi, President and Chief Executive Officer.
- Motley Fool•17 days ago
3 Small-Cap Biotech Stocks to Watch Now
These under-the-radar stocks could be poised to make big moves in the coming months.
- GlobeNewswire•19 days ago
Evolus Provides Regulatory Update on Nuceiva™ in the European Union
Nuceiva™ (branded Jeuveau™ in the United States) is being evaluated by the EMA for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age. “We are actively addressing the CHMP’s final few questions in accordance with their timelines, which will enable them to adopt their formal opinion on our MAA during the April Committee meeting,” said Rui Avelar, MD, Chief Medical Officer and Head of Research & Development at Evolus, Inc. “In the second quarter, in addition to an opinion in Europe, we look forward to publishing the largest head-to-head aesthetic pivotal trial of our neurotoxin versus BOTOX®, which was conducted in Europe and Canada.
- Motley Fool•26 days ago
Why Penn Virginia, Evolus, and Cousins Properties Slumped Today
Merger and acquisition moves played a role in the declines for two of these stocks.
- Zacks•last month
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
- GlobeNewswire•last month
Evolus Announces Publication of U.S. Phase III Pivotal Trial Results for Jeuveau™ in Dermatologic Surgery
Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the publication of the U.S. Phase III pivotal trial results for Jeuveau™ in Dermatologic Surgery. The article titled, “Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results from 2 Identical Phase III Studies”, is now available on the Journal’s Website and will be printed in the March 2019 issue. “As a principal investigator in EV-001 and EV-002, and first author on the paper, I am confident in the robustness of these results.
- Zacks•last month
NASH, Allergies and Beauty Stocks: Invest or Not?
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?
- Motley Fool•last month
Why Evolus Stock Is Soaring 12% Higher Today
There are no frown lines from investors as the company is about to launch a competitor to Botox.
- GlobeNewswire•last month
Evolus Reports Fourth Quarter and Full Year 2018 Results
Received U.S. FDA Approval of Jeuveau™ on February 1, 2019 Majority of Sales Force Hired with Launch Planned in the Coming Weeks Hosting Investor & Analyst Day on May 8th,.
- GlobeNewswire•last month
Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC
NEWPORT BEACH, Calif., March 18, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
- GlobeNewswire•last month
Evolus to Release Fourth Quarter and Full Year 2018 Financial Results and Provide a Business Update on Monday, March 18, 2019
IRVINE, Calif., March 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
- Simply Wall St.•last month
Evolus, Inc.’s (NASDAQ:EOLS) Path To Profitability
Evolus, Inc.'s (NASDAQ:EOLS): Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. With the latest financial year loss of -US$4.5m and a trailing-twelve monthRead More...
- Zacks•last month
Implied Volatility Surging for Evolus (EOLS) Stock Options
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
- GlobeNewswire•2 months ago
Evolus Appoints Crystal Muilenburg as Vice President Corporate Communications & Public Relations
NEWPORT BEACH, Calif., Feb. 27, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on delivering breakthrough products, today announced the appointment.
- Motley Fool•2 months ago
2 Frustrating Flops, Plus Welcome to the Wrinkle Wars
Disappointing data from Gilead Sciences and Sangamo weigh on investors, while one tiny stock challenges Allergan.
- Zacks•2 months ago
Allergan Responds to Investor's Call for CEO/Chair Role Split
Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
- MarketWatch•2 months ago
Harry Boxer’s stocks to watch include maker of Botox competitor
Here are two stocks moving higher on news and two others showing weakening technical indicators. American Superconductor (AMSC) jumped 66 cents to $14.54 Thursday on 604,100 shares traded, or double the average volume.
- TheStreet.com•2 months ago
Evolus Stockholders May Be Frowning in the Short Run
In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with David Moatazedi, president and CEO of Evolus Inc. with a new drug to compete with Botox. Shares of EOLS have surged from $16 to $29 after the company received FDA approval on Friday.
- CNBC•2 months ago
Cramer Remix: If the market drops tomorrow, buy this stock
Jim Cramer explains why Cisco could be a winner if the market heads lower.
- Motley Fool•2 months ago
Why Leggett & Platt, Mueller Industries, and Evolus Jumped Today
These stocks helped lead Wall Street higher.
- TheStreet.com•2 months ago
Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management
Billionaire David Tepper, president of hedge fund Appaloosa LP, fired off a letter Tuesday demanding the Dublin-based pharmaceutical firm separate the roles of chairman and CEO. Following the release of the letter, Allergan's stock fell 0.4% Tuesday to close at $138.01. "The Board of Directors is committed to strong governance practices and independent board leadership," Allergan said in its statement.
- Zacks•2 months ago
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
- Associated Press•2 months ago
Papa John's, Evolus rise; Gannett, Allergan slip
Stocks that moved substantially or traded heavily on Monday: Papa John's International Inc., up $ 3.46 to $41.97 The head of the investment firm Starboard Value is being named board chairman at the troubled ...
- TheStreet.com•2 months ago
Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox
shares fell almost 4% and Evolus Inc. shares gained almost 12% Monday after the U.S. Food and Drug Administration approved Evolus's new wrinkle treatment for adult patients which is expected to rival Allergan's Botox. The treatment, called Jeuveau, received FDA approval late Friday, some eight months after the agency first rejected the application citing deficiencies in its manufacturing and chemical composition.
- CNBC Videos•2 months ago
Aesthetics company behind latest Botox rival was 'designed' to compete with Botox: CEO
Jim Cramer hears from Evolus President and CEO David Moatazedi about his company's cheaper rival to Allergan's Botox.
